Adar Poonawalla became CEO of Serum Institute in 2011, a company his father founded in 1966.
Under his leadership it became the world's largest vaccine maker by volume, and a critical supplier during COVID-19.
The Story:
Cyrus Poonawalla founded Serum Institute in Pune in 1966. His son Adar joined in 2001 and became CEO in 2011.
He pursued WHO pre-qualification, which opened the door to UN procurement, and widened exports far beyond India.
When COVID-19 arrived, Serum partnered with AstraZeneca to produce Covishield and ramped capacity ahead of orders.
India's government received over 1.4 billion doses, and Forbes India reported COVID vaccine capacity reaching about 4 billion doses a year.
By 2023, the company made roughly 1.9 billion doses across its range, and its R21 malaria vaccine earned a WHO recommendation.
Business Insight:
Vaccines reward manufacturing scale and regulatory credibility.
Serum's WHO pre-qualification gave it access to the world's largest buyers, so when COVID struck, the capacity and the trust were already in place.
The FundForge Take:
A founder's legacy is a head start, not a strategy.
Adar Poonawalla's bet was that a family firm in Pune could be a global utility. The pandemic tested that claim, and the numbers back it up.
